## **Data Sharing Statement**

Waring, IV. Safety and Efficacy of Pilocarpine Hydrochloride, 1.25%, in Individuals With Presbyopia. *JAMA Ophthalmol*. Published March 03, 2022. doi:10.1001/jamaophthalmol.2022.0059

Data

Data available: Yes

**Data types:** Other (please specify)

**Additional Information:** AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (eg, protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

How to access data: This clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: <a href="https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html">https://www.abbvie.com/our-science/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</a>.

When available: With publication

Supporting Documents Document types: None

## **Additional Information**

Who can access the data: Any qualified researchers who engage in rigorous, independent scientific research, following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement.

**Types of analyses:** Anonymized, individual, and trial-level data (analysis data sets), as well as other information (eg, protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission and following review and approval of the research proposal and SAP by AbbVie and execution of the data sharing agreement. **Mechanisms of data availability:** Following review and approval of a research proposal and

Statistical Analysis Plan (SAP) and signing of a Data Sharing Agreement.